D., Allwright (2011) Interpreting pharmaceutical screening test results. [Study Group Report]
|
PDF
6MB |
Abstract
In the pharmaceutical industry, compounds are tested for activity against
a disease target. In a High Throughput Assay (HTA), each compound is
tested at a single concentration. In an IC50 test, a compound is tested
at a range of concentrations. Sometimes there are discrepancies between
the results of these tests and the Study Group was asked to model this.
Rather than assume normally distributed errors in the percentage effect,
the Study Group proposed a model in which there are also probabilities
p and q of a test erroneously indicating very low or high activity. The
parameters p and q can be estimated from the data, and then can be
used in the design of testing procedures.
Item Type: | Study Group Report |
---|---|
Problem Sectors: | Medical and pharmaceutical |
Study Groups: | European Study Group with Industry > ESGI 80 (Cardiff, UK, Apr 4-8, 2011) |
Company Name: | Pfizer Worldwide R&D |
ID Code: | 578 |
Deposited By: | Mark Curtis |
Deposited On: | 22 Mar 2012 16:10 |
Last Modified: | 29 May 2015 20:12 |
Repository Staff Only: item control page